with the Angelman data, so three positive trials all in a row, Pilcher and his team have finally achieved their main goal, that is to read and understand if 2591 is able to offer itself as a platform for the master trial which is the one on the autism spectrum. from the very clear words of Pilcher last thursday it emerged very clearly that all this is reality and therefore must be applied. they also told us that Neuren's financial resources will be able to satisfy a couple of phase 3, provided that the protocol dictated by the FDA is not particularly demanding and therefore more expensive than expected. certainly Neuren will not be able today or ever to independently face a trial of enormous proportions like the one on autism. in essence it is clear to everyone that such trials are for big pharma where Acadia is not located.the path is MARKED and Pilcher made it clear like never before in the past. after the FDA meeting those famous "strategic options" that we have been hearing about for over a year will be decided. the time is ripe and for those who still have a pinch of patience to spend, in a few days we will have news as milestones.now I come to my demonstration that what I have stated is in Neuren's plans from 2021. these are not my conjectures or suppositions, but the words and facts of Neuren and its CEO Pilcher.follow the following carefully:
as it should be, it all revolves around this patent:October 11, 2021US Patent through 2034 Granted for Neuren's NNZ-2591 in Autism Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) has received a notice of clearance from the United States Patent and Trademark Office for a new patent covering NNZ-2591 for the treatment of autism. The patent, titled "Bicyclic Compounds and Methods for Use Thereof in the Treatment of Autism," extends through July 2034. Similar applications have previously been granted in Europe and Japan. Neuren is currently developing NNZ-2591 for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Willi syndromes, four serious, lifelong neurological disorders that emerge in early childhood. Neuren CEO Jon Pilcher commented: "We have seen that NNZ-2591's mechanism of action appears to have broad utility in neurodevelopmental disorders. Considering that autism is estimated to affect one in 160 children, the granting of this important US patent could potentially open the way to a great future opportunity as we learn more about the causes of autism."now why and after pilcher's words last Thursday seem to have become reality !!! so in hindsight, it seems that these four studies have served what I highlighted in bold. I add :: pilcher Thursday in regards to questions about potential new pathologies observed for 2591, said that as soon as they are sure of what they have observed, they will make official statements. given that it talks about multiple pathologies, doesn't it make more sense to open a single trial on autism as a "great future opportunity"? future was in 2021 !!! now ....????
Expand
(20min delay)